PTPRC and diffuse large B-cell lymphoma: Flow cytometry analysis of cell surface markers (CD45, CD19, CD3, CD20, and kappa) (Supplementary Fig. 8a) in cells isolated from four patient biopsies after incubation or not with 177Lu-lilotomab alone or in combination with MK-1775 or PD-166285 for 18 h showed that the proportion of living malignant cells (CD3-negative and CD20 and kappa positive) was higher in nontreated FL (27.1–29.9%) than in nontreated DLBCL (0.36–0.52%) samples.